Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309242 | 0.87 | OPRL1 (0.43) | KMT2AKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL24162066 | 0.85 | KMT2A (0.43) | KMT2AKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL24596435 | 0.72 | OPRL1 (0.43) | KMT2AKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL24309149 | 0.68 | OPRM1 (0.42) | KMT2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL24309156 | 0.68 | MEN1 (0.42) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24596440 | 0.63 | POLB (0.44) | PDE4APDE4BPDE4CPDE4DSLC6A3 | |
| SCHEMBL7677681 | 0.63 | OPRM1 (0.44) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22365590 | 0.62 | SIGMAR1 (0.44) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6042898 | 0.62 | KMT2A (0.82) | KMT2AKDM4EOPRM1OPRL1 | |
| SCHEMBL6577299 | 0.60 | OPRM1 (0.46) | KMT2AKDM4ESLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | KMT2A 1092/4885KDM4E 988/4885PDE4A 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.